HOUT-04. DEMOGRAPHIC PROFILES, MANAGEMENT AND CLINICAL OUTCOMES OF GLIOBLASTOMA PATIENTS TREATED AT ST. LUKE’S MEDICAL CENTER- PHILIPPINES Free

Glioblastoma is a highly aggressive primary brain tumor and typically treated with maximal safe resection followed by concomitant radiation and temozolomide followed by 6 cycles of adjuvant temozolomide.

We reviewed histologically documented glioblastoma cases seen and treated at our center from 2005 until 2017. Demographic data, treatments received, PFS and OS were collected.

105 GBM patients were treated with a median age of 45 and KPS 90. Fifty five percent (58/105) had gross total resection, 18% subtotal resection and 13% biopsy. Seventy percent (74/105) were treated with RT plus TMZ, 15 %(16/105) RT alone and 1 patient treated with TMZ alone. The most common adverse events are fatigue and somnolence. Median follow up is 10.5 months. Progression free survival (PFS) is 13.38 months while overall survival (OS) is 15.43 months.

This is the first study done for glioblastoma patients in the Philippines treated after surgery with RT plus concomitant and adjuvant TMZ. The results are consistent with the published data.